Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-11-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于控股子公司在研产品获FDA批准上市的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about its subsidiary's investigational product receiving FDA approval for marketing. It details the product, clinical trial results, regulatory milestones, commercial agreements, and potential impact on the company. The document is about a regulatory approval event and commercial licensing agreements, not a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management discussion. The document is a formal announcement of a significant regulatory milestone and business development, fitting best into the category of a Regulatory Filing (RNS) as it does not contain financial statements or detailed financial analysis but provides important regulatory and business update information.
2023-11-17 Chinese
关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a guarantee provided by the company to its wholly-owned subsidiary. It details the guarantee contract, financial data of the subsidiary, board approvals, and cumulative guarantee amounts. There is no indication that this is a full financial report, audit report, or earnings release. The document is a formal disclosure about a financing-related guarantee arrangement, which fits best under Capital/Financing Update (CAP). The document length is 2485 characters, which is relatively short but contains substantive information about financing guarantees, not just a brief notice or a report publication announcement. Therefore, the classification is CAP with high confidence.
2023-11-14 Chinese
关于全资子公司参与全国药品集中采购拟中选的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary's participation and tentative selection in a national centralized drug procurement process. It includes details about the product, procurement prices, regions, and potential impact on the company. The document is short (1212 characters) and does not contain financial statements or detailed financial analysis. It is an announcement of a business event related to procurement results, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a business development that does not fit other specific categories.
2023-11-07 Chinese
关于2022年员工持股计划锁定期届满的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the expiration of the lock-up period of its 2022 employee stock ownership plan. It details the stock purchase completion, lock-up period dates, and subsequent arrangements for selling the shares. The document does not contain financial statements or detailed financial analysis but serves as a regulatory disclosure about the employee stock plan status and compliance with trading rules. It is not an annual report, interim report, or earnings release. It is also not a management change, voting result, or capital change announcement. Given the nature of the content as a formal announcement about the employee stock plan lock-up expiration and related compliance, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories. The document length is short (1842 characters), consistent with an announcement rather than a full report.
2023-11-05 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the board's approval of the share buyback, the intended use of funds, and the status update that no shares have been repurchased as of the specified date. It does not contain financial statements or detailed financial data but is an update on capital activity. Therefore, it fits the category of Transaction in Own Shares (POS). The document length and content confirm it is not a full report but a specific announcement about share repurchase progress.
2023-11-01 Chinese
独立董事对第八届董事会第十次会议相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is titled as an "Independent Directors' Independent Opinion" related to the company's 8th Board of Directors 10th meeting. It discusses the independent directors' opinion on the use of idle raised funds to temporarily supplement working capital, referencing relevant laws and company regulations. The document is short (780 characters) and contains no financial statements or detailed financial data. It is a formal opinion or statement from independent directors rather than a full audit report or annual report. This fits best under Audit Report / Information (AR), as it relates to audit or independent opinions on company financial matters but is not a full annual report or earnings release. Q3 2023
2023-10-30 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.